The U.S. Supreme Court has decided not to hear appeals from pharmaceutical firms challenging the Medicare drug price negotiation program, marking a significant moment in the ongoing debate over drug pricing. This decision leaves intact the rulings of the federal appeals court in Philadelphia, which previously dismissed the pharmaceutical companies’ arguments.
Established under the 2022 Inflation Reduction Act, the negotiation initiative allows for direct price negotiations between the federal government and drug manufacturers, specifically targeting high-cost medications for Medicare. The program is set to launch its first negotiated deals in 2026, altering years of contention over federal involvement in drug pricing.
Despite unified Republican opposition to the legislation, President Joe Biden signed it into law, underscoring a stark partisan divide. The Republican stance has been critical of the Act, with former President Donald Trump having previously reversed initiatives favoring alternative energy sources. Nevertheless, the Biden administration has embraced the negotiation authority to reduce prescription costs.
To date, negotiations have successfully targeted 25 medications covered by Medicare, including the popular GLP-1 weight-loss and diabetes treatments, Ozempic, Rybelsus, and Wegovy. In a move from January, the Trump administration identified additional drugs for a future negotiation round, potentially increasing the number of medications with reduced costs for Medicare beneficiaries to 40.
Pharmaceutical companies have strongly resisted the program, maintaining that cost-cutting measures should focus on insurers and pharmacy benefit managers instead. However, without judicial relief, altering the program’s trajectory may require Congressional intervention, as the statute currently has no expiration.
